JP2013508292A - ＥｐｈＡ３に対する抗体 - Google Patents

ＥｐｈＡ３に対する抗体 Download PDF

Info

Publication number
JP2013508292A
JP2013508292A JP2012534368A JP2012534368A JP2013508292A JP 2013508292 A JP2013508292 A JP 2013508292A JP 2012534368 A JP2012534368 A JP 2012534368A JP 2012534368 A JP2012534368 A JP 2012534368A JP 2013508292 A JP2013508292 A JP 2013508292A
Authority
JP
Japan
Prior art keywords
seq
antibody
region
amino acid
segment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012534368A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013508292A5 (enExample
Inventor
ケニス リュールセン
デイビッド マルチネス
クリスティーナ イ
クリストファー アール． ベッビントン
ジェフリー ティー． ヤラントン
Original Assignee
カロバイオス ファーマシューティカルズ インコーポレイティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カロバイオス ファーマシューティカルズ インコーポレイティッド filed Critical カロバイオス ファーマシューティカルズ インコーポレイティッド
Publication of JP2013508292A publication Critical patent/JP2013508292A/ja
Publication of JP2013508292A5 publication Critical patent/JP2013508292A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2012534368A 2009-10-14 2010-10-14 ＥｐｈＡ３に対する抗体 Pending JP2013508292A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25166809P 2009-10-14 2009-10-14
US61/251,668 2009-10-14
PCT/US2010/052725 WO2011053465A1 (en) 2009-10-14 2010-10-14 Antibodies to epha3

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015229465A Division JP2016094424A (ja) 2009-10-14 2015-11-25 ＥｐｈＡ３に対する抗体

Publications (2)

Publication Number Publication Date
JP2013508292A true JP2013508292A (ja) 2013-03-07
JP2013508292A5 JP2013508292A5 (enExample) 2013-11-28

Family

ID=43499991

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012534368A Pending JP2013508292A (ja) 2009-10-14 2010-10-14 ＥｐｈＡ３に対する抗体
JP2015229465A Pending JP2016094424A (ja) 2009-10-14 2015-11-25 ＥｐｈＡ３に対する抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015229465A Pending JP2016094424A (ja) 2009-10-14 2015-11-25 ＥｐｈＡ３に対する抗体

Country Status (11)

Country Link
US (2) US8664365B2 (enExample)
EP (1) EP2488554B1 (enExample)
JP (2) JP2013508292A (enExample)
CN (1) CN102666589B (enExample)
AU (1) AU2010313621C1 (enExample)
CA (1) CA2777068C (enExample)
DK (1) DK2488554T3 (enExample)
ES (1) ES2743558T3 (enExample)
PL (1) PL2488554T3 (enExample)
PT (1) PT2488554T (enExample)
WO (1) WO2011053465A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011123819A2 (en) * 2010-04-01 2011-10-06 Kalobios Pharmaceuticals, Inc. Epha3 antibodies for the treatment of multiple myeloma
EP2582388A4 (en) * 2010-06-18 2014-04-16 Kalobios Pharmaceuticals Inc IDENTIFYING EPHA3 AS A MARKER FOR THE PRESENCE OF A SOLID TUMOR
EP2741774A4 (en) * 2011-08-12 2015-05-20 Kalobios Pharmaceuticals Inc METHOD FOR THE TREATMENT OF HEMATOLOGIC PROLIFERATIVE DISEASES BY TARGETING EPHA3 EXPRESSED ON ABERRANT VACCINATION SYSTEM IN THE BONE MARROW
CN105452296B (zh) 2013-08-01 2020-09-25 戊瑞治疗有限公司 无岩藻糖基化抗fgfr2iiib抗体
RU2745707C2 (ru) 2015-11-23 2021-03-30 Файв Прайм Терапьютикс, Инк. Ингибиторы fgfr2 отдельно или в комбинации с иммуностимулирующими агентами в лечении рака
EP3512883A1 (en) 2016-09-13 2019-07-24 Humanigen, Inc. Epha3 antibodies for the treatment of pulmonary fibrosis
LT3624837T (lt) 2017-05-16 2025-10-10 Anti-fgfr2 antikūnai derinyje su chemoterapijos agentais vėžio gydymui
US11795221B2 (en) 2018-02-28 2023-10-24 WuXi Biologics Ireland Limited Monoclonal antibody against human LAG-3, method for preparing the same, and use thereof
IL291937A (en) * 2019-10-09 2022-06-01 Council Queensland Inst Medical Res Direct link to epha3 and its uses
AR120430A1 (es) * 2019-11-08 2022-02-16 Humanigen Inc Células car-t dirigidas a epha3 para el tratamiento de tumores
EP4232470A4 (en) * 2020-10-23 2025-01-15 Atreca, Inc. ANTIBODIES AGAINST CORONAVIRUS SARS-COV-2
JP7726496B2 (ja) * 2021-08-06 2025-08-20 コリア リサーチ インスティチュート オブ バイオサイエンス アンド バイオテクノロジー 新規な抗ＥｐｈＡ２キメラ抗原受容体及びそれを発現する免疫細胞

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050255552A1 (en) * 2004-01-20 2005-11-17 Kalobios, Inc. Antibody specificity transfer using minimal essential binding determinants
WO2008112192A2 (en) * 2007-03-08 2008-09-18 Kalobios Pharmaceuticals, Inc. Epha3 antibodies for the treatment of solid tumors

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
CA2111006C (en) 1991-06-21 2008-04-08 Andrew D. Boyd A novel receptor-type tyrosine kinase and use thereof
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
NO175798C (no) 1992-07-22 1994-12-07 Sinvent As Fremgangsmåte og anordning til aktiv stöydemping i et lokalt område
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
ATE440959T1 (de) 2000-06-28 2009-09-15 Glycofi Inc Verfahren für die herstellung modifizierter glykoproteine
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン，エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
EP2339004B1 (en) 2002-03-19 2015-02-25 Stichting Dienst Landbouwkundig Onderzoek Optimizing glycan processing in plants
WO2004029207A2 (en) 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
AU2005277641A1 (en) 2004-08-16 2006-03-02 Medimmune, Llc Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
US8222253B2 (en) * 2004-10-23 2012-07-17 Case Western Reserve University Peptide and small molecule agonists of EphA and their uses
EP2343380B1 (en) 2004-11-16 2019-06-12 Humanigen, Inc. Immunoglobulin variable region cassette exchange
US8211648B2 (en) 2005-07-22 2012-07-03 Kalobios Pharmaceuticals, Inc. Secretion of antibodies without signal peptides from bacteria
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
WO2008060092A1 (en) 2006-11-17 2008-05-22 Sang Yun Park Rotative force generator
CL2008002782A1 (es) 2007-09-21 2009-07-31 Genentech Inc Anticuerpo anti-bv8 neutralizante; composicion que lo comprende; y su uso para tratar tumores en humanos previamente tratados con un antagonista del factor de crecimiento endotelial vascular.
WO2010102244A1 (en) 2009-03-06 2010-09-10 Kalobios Pharmaceuticals, Inc. Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050255552A1 (en) * 2004-01-20 2005-11-17 Kalobios, Inc. Antibody specificity transfer using minimal essential binding determinants
WO2008112192A2 (en) * 2007-03-08 2008-09-18 Kalobios Pharmaceuticals, Inc. Epha3 antibodies for the treatment of solid tumors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN5012017541; Ａｒｒｕｇａ　Ｆｒａｎｃｅｓｃａ　ｅｔ　ａｌ．: '"ＥｐｈＡ３　ｉｓ　ａｂｎｏｒｍａｌｌｙ　ｅｘｐｒｅｓｓｅｄ　ｉｎ　ｃｈｒｏｎｉｃ　ｍｙｅｌｏｐｒｏｌｉｐｈｅｒａｔｉｖｅ　ｄｉｓｏｒｄｅｒｓ　ａｎｄ　ｃｏｕｌｄ　ｒｅｐｒｅｓｅｎｔ　ａ　ｎｅｗ　ｍｏ' ＰＲＯＣＥＥＤＩＮＧＳ　ＯＦ　ＴＨＥ　ＡＮＮＵＡＬ　ＭＥＥＴＩＮＧ　ＯＦ　ＴＨＥ　ＡＭＥＲＩＣＡＮ　ＡＳＳＯＣＩＡＴＩＯＮ　ＦＯＲ　ＣＡＮＣＥＲ　ＲＥＳＥＡＲＣＨ ｖｏｌ．　５０，　１, 20090401, ｐ．　６９２, ＡＭＥＲＩＣＡＮ　ＡＳＳＯＣＩＡＴＩＯＮ　ＦＯＲ　ＣＡＮ&# *
JPN5012017542; Ｃｉｌｌｏｎｉ　Ｄａｎｉｅｌａ　ｅｔ　ａｌ．: '"ＥｐｈＡ３　Ｋｉｎａｓｅ　Ｉｓ　Ｃｏｎｓｔｉｔｕｔｉｖｅｌｙ　Ａｃｔｉｖａｔｅｄ　ｉｎ　Ｃｈｒｏｎｉｃ　Ｍｙｅｌｏｉｄ　Ｌｅｕｋａｅｍｉａ　ｄｕｒｉｎｇ　Ｐｒｏｇｒｅｓｓｉｏｎ　ｔｏ　Ａｃｃｅｌｅｒ' ＢＬＯＯＤ ｖｏｌ．　１１２，　ｎｏ．　１１, 20081101, ｐ．　３９９, ＡＭＥＲＩＣＡＮ　ＳＯＣＩＥＴＹ　ＯＦ　ＨＥＭＡＴＯＬＯＧＹ *
JPN6014049912; Ｌｉｓｔ　Ａ: '"Ｄｅｖｅｌｏｐｍｅｎｔａｌ　ｔｈｅｒａｐｅｕｔｉｃｓ　ｆｏｒ　ＭＤＳ"' ＬＥＵＫＥＭＩＡ　ＲＥＳＥＡＲＣＨ ｖｏｌ．　３３，　ｎｏ．　Ｓｕｐｐｌ．　１, 200905, ｐ．　Ｓ２７-Ｓ２８ *

Also Published As

Publication number Publication date
EP2488554B1 (en) 2019-07-24
CA2777068C (en) 2020-05-26
EP2488554A1 (en) 2012-08-22
PL2488554T3 (pl) 2020-03-31
CA2777068A1 (en) 2011-05-05
AU2010313621A1 (en) 2012-05-03
ES2743558T3 (es) 2020-02-19
CN102666589A (zh) 2012-09-12
US8664365B2 (en) 2014-03-04
CN102666589B (zh) 2014-08-20
AU2010313621B2 (en) 2015-07-30
PT2488554T (pt) 2019-09-13
DK2488554T3 (da) 2019-09-02
JP2016094424A (ja) 2016-05-26
US20140120114A1 (en) 2014-05-01
US20110123549A1 (en) 2011-05-26
US9290571B2 (en) 2016-03-22
AU2010313621C1 (en) 2015-11-26
WO2011053465A1 (en) 2011-05-05

Similar Documents

Publication Publication Date Title
US9290571B2 (en) Antibodies to EphA3
JP2022545585A (ja) 新規の抗ｃｄ３９抗体
JP2022545300A (ja) 新規の抗ｓｉｒｐａ抗体
CN107849136A (zh) 抗TfR抗体及其在治疗增殖性和炎性疾病中的用途
CA3160812A1 (en) Novel anti-fgfr2b antibodies
KR20230110523A (ko) 델타-유사 리간드 3(dll3) 항원 결합 영역을 포함하는 단백질 및 그의 용도
MX2013015061A (es) Anticuerpo anti-cxcr4 con funciones efectoras y su uso para el tratamiento del cancer.
JP2023531247A (ja) クローディン関連疾患を処置するための抗体および方法
TW202313699A (zh) 新型抗ｓｉｒｐａ抗體
US20240279341A1 (en) Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
TW202227498A (zh) 新型抗ｃｌａｕｄｉｎ１８抗體
JP2026504816A (ja) 抗ｆｇｆｒ２ｂ抗体及びその用途
WO2022166846A1 (zh) 抗tnfr2抗体及其用途
US9045539B2 (en) Anti-EMR1 antibodies
KR20240004694A (ko) 항체
WO2025067442A1 (zh) 抗fgfr2抗体和包含其的多特异性结合分子
HK40109194A (zh) 抗体
JP2014527054A (ja) 骨髄内の異常血管系上に発現したＥｐｈＡ３を標的とすることによる、血液増殖性疾患を処置する方法
EA053247B1 (ru) Антитела к ctla4 и способы их применения
NZ618655B2 (en) Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131011

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150525

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150618

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150727